The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

AIDS

Volumn 24, Issue 1, 2010, Pages 123-137

  Hernán, Miguel A ^a  

^a NONE

Author keywords

Antiretroviral therapy; HIV infection; Inverse probability weighting; Marginal structural models; Mortality

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; THERAPY EFFECT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; UNITED STATES; VIRAL LOAD;

EID: 73649107271     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283324283     Document Type: Article

References (39)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez CC, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
3. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
4. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
5. Cameron DW, Heath-Chiozzi M, DannerS, CohenC, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of rito-navir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-549.
6. Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet 1998; 351:536-537.
7. Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4R lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993; 118:674-680.
8. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993; 12:835-842.
9. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group. AIDS 1999; 13:565-573.
10. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12:1823-1832.
11. Lewden C, Chene G, Morlat P, Raffi F, Dabis F, Leport C. Mortality rate of HIV-infected adults compared with the general population: long-term and CD4-lymphocyte-dependent results. Med Sci (Paris) 2008; 24:804-806.
12. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active anti-retroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
13. Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22: 89-95.
14. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685-692.
15. Perez-Hoyos S, Ferreros I, del Amo J, Muga R, del Romero J, Garcia de Olalla P, Hernandez-Aguado I. Survival and progression to AIDS in a seroconverter cohort in the posthighly active antiretroviral therapy era: effectiveness goes on. AIDS 2006; 20:289-291.
16. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
17. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS, CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
18. Mocroft A, Phillips AN, Lundgren JD. HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med 2004; 140:578-579; author reply 579.
19. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
20. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
21. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
22. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17:2227-2236. (Pubitemid 37338896)
23. Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarc-hand M, Abramowitz L, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-1211.
24. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868. (Pubitemid 29126872)
25. Jaen A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008; 47:212-220.
26. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamc-zer D, Rubio R, et al. Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results. Enferm Infecc Microbiol Clin 2007; 25:23-31.
27. Moreno S, Jarrin I, Iribarren JA, Perez-Elias MJ, Vician P, Parra-Ruiz J, et al. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis 2008; 12:1393-1400.
28. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44 (8 Suppl 2):S13-S24.
29. The UK register of HIV seroconverters: methods and analytical issues. UK register of HIV seroconverters (UKRHS) Steering Committee. Epidemiol Infect 1996; 117:305-312.
30. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS ONE 2008; 3:e3907.
31. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18:2361-2369.
32. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garćia de Olalla P, Guerrero R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconver-ters: differences by transmission category. AIDS 2003; 17:353-359.
33. - 1993 revised classification system for HIV infection and expanded surveillance case definition for AI DS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41:1-19.
34. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9:1501-1515.
35. Hernan MA, Hernandez-D́iaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15:615-625.
36. Robins JM. Marginal structural models. Paper presented at 1997 Proceedings of the Section on Bayesian Statistical Science. American Statistical Association; 1998; Alexandria, VA.
37. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antire-troviral therapy: New York City. Ann Intern Med 2006; 145:397-406.
38. Celentano DD. Mortality among urban drug users and the impact of highly active antiretroviral therapy. Clin Infect Dis 2005; 41:873-874.
39. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.